Surgical management of advanced gastric cancer: An evolving issue

Luigi Marano, K. Polom, A. Patriti, G. Roviello, Giuseppe Falco, A. Stracqualursi, Raffaele De Luca, Roberto Petrioli, M. Martinotti, D. Generali, Daniele Marrelli, N. Di Martino, Franco Roviello

Research output: Contribution to journalArticle

Abstract

Worldwide, gastric cancer represents the fifth most common cancer and the third leading cause of cancer deaths. Although the overall 5-year survival for resectable disease was more than 70% in Japan due to the implementation of screening programs resulting in detection of disease at earlier stages, in Western countries more than two thirds of gastric cancers are usually diagnosed in advanced stages reporting a 5-year survival rate of only 25.7%. Anyway surgical resection with extended lymph node dissection remains the only curative therapy for non-metastatic advanced gastric cancer, while neoadjuvant and adjuvant chemotherapies can improve the outcomes aimed at the reduction of recurrence and extension of survival. High-quality research and advances in technologies have contributed to well define the oncological outcomes and have stimulated many clinical studies testing multimodality managements in the advanced disease setting. This review article aims to outline and discuss open issues in current surgical management of advanced gastric cancer.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalEuropean Journal of Surgical Oncology
Volume42
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Stomach Neoplasms
Adjuvant Chemotherapy
Lymph Node Excision
Early Diagnosis
Cause of Death
Neoplasms
Japan
Survival Rate
Technology
Recurrence
Research
Therapeutics

Keywords

  • Advanced gastric cancer
  • HIPEC
  • Laparoscopic surgery
  • Lymphadenectomy
  • Robotic surgery

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Marano, L., Polom, K., Patriti, A., Roviello, G., Falco, G., Stracqualursi, A., ... Roviello, F. (2016). Surgical management of advanced gastric cancer: An evolving issue. European Journal of Surgical Oncology, 42(1), 18-27. https://doi.org/10.1016/j.ejso.2015.10.016

Surgical management of advanced gastric cancer : An evolving issue. / Marano, Luigi; Polom, K.; Patriti, A.; Roviello, G.; Falco, Giuseppe; Stracqualursi, A.; De Luca, Raffaele; Petrioli, Roberto; Martinotti, M.; Generali, D.; Marrelli, Daniele; Di Martino, N.; Roviello, Franco.

In: European Journal of Surgical Oncology, Vol. 42, No. 1, 01.01.2016, p. 18-27.

Research output: Contribution to journalArticle

Marano, L, Polom, K, Patriti, A, Roviello, G, Falco, G, Stracqualursi, A, De Luca, R, Petrioli, R, Martinotti, M, Generali, D, Marrelli, D, Di Martino, N & Roviello, F 2016, 'Surgical management of advanced gastric cancer: An evolving issue', European Journal of Surgical Oncology, vol. 42, no. 1, pp. 18-27. https://doi.org/10.1016/j.ejso.2015.10.016
Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A et al. Surgical management of advanced gastric cancer: An evolving issue. European Journal of Surgical Oncology. 2016 Jan 1;42(1):18-27. https://doi.org/10.1016/j.ejso.2015.10.016
Marano, Luigi ; Polom, K. ; Patriti, A. ; Roviello, G. ; Falco, Giuseppe ; Stracqualursi, A. ; De Luca, Raffaele ; Petrioli, Roberto ; Martinotti, M. ; Generali, D. ; Marrelli, Daniele ; Di Martino, N. ; Roviello, Franco. / Surgical management of advanced gastric cancer : An evolving issue. In: European Journal of Surgical Oncology. 2016 ; Vol. 42, No. 1. pp. 18-27.
@article{961712262027446fa9a6be7badd02373,
title = "Surgical management of advanced gastric cancer: An evolving issue",
abstract = "Worldwide, gastric cancer represents the fifth most common cancer and the third leading cause of cancer deaths. Although the overall 5-year survival for resectable disease was more than 70{\%} in Japan due to the implementation of screening programs resulting in detection of disease at earlier stages, in Western countries more than two thirds of gastric cancers are usually diagnosed in advanced stages reporting a 5-year survival rate of only 25.7{\%}. Anyway surgical resection with extended lymph node dissection remains the only curative therapy for non-metastatic advanced gastric cancer, while neoadjuvant and adjuvant chemotherapies can improve the outcomes aimed at the reduction of recurrence and extension of survival. High-quality research and advances in technologies have contributed to well define the oncological outcomes and have stimulated many clinical studies testing multimodality managements in the advanced disease setting. This review article aims to outline and discuss open issues in current surgical management of advanced gastric cancer.",
keywords = "Advanced gastric cancer, HIPEC, Laparoscopic surgery, Lymphadenectomy, Robotic surgery",
author = "Luigi Marano and K. Polom and A. Patriti and G. Roviello and Giuseppe Falco and A. Stracqualursi and {De Luca}, Raffaele and Roberto Petrioli and M. Martinotti and D. Generali and Daniele Marrelli and {Di Martino}, N. and Franco Roviello",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2015.10.016",
language = "English",
volume = "42",
pages = "18--27",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Surgical management of advanced gastric cancer

T2 - An evolving issue

AU - Marano, Luigi

AU - Polom, K.

AU - Patriti, A.

AU - Roviello, G.

AU - Falco, Giuseppe

AU - Stracqualursi, A.

AU - De Luca, Raffaele

AU - Petrioli, Roberto

AU - Martinotti, M.

AU - Generali, D.

AU - Marrelli, Daniele

AU - Di Martino, N.

AU - Roviello, Franco

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Worldwide, gastric cancer represents the fifth most common cancer and the third leading cause of cancer deaths. Although the overall 5-year survival for resectable disease was more than 70% in Japan due to the implementation of screening programs resulting in detection of disease at earlier stages, in Western countries more than two thirds of gastric cancers are usually diagnosed in advanced stages reporting a 5-year survival rate of only 25.7%. Anyway surgical resection with extended lymph node dissection remains the only curative therapy for non-metastatic advanced gastric cancer, while neoadjuvant and adjuvant chemotherapies can improve the outcomes aimed at the reduction of recurrence and extension of survival. High-quality research and advances in technologies have contributed to well define the oncological outcomes and have stimulated many clinical studies testing multimodality managements in the advanced disease setting. This review article aims to outline and discuss open issues in current surgical management of advanced gastric cancer.

AB - Worldwide, gastric cancer represents the fifth most common cancer and the third leading cause of cancer deaths. Although the overall 5-year survival for resectable disease was more than 70% in Japan due to the implementation of screening programs resulting in detection of disease at earlier stages, in Western countries more than two thirds of gastric cancers are usually diagnosed in advanced stages reporting a 5-year survival rate of only 25.7%. Anyway surgical resection with extended lymph node dissection remains the only curative therapy for non-metastatic advanced gastric cancer, while neoadjuvant and adjuvant chemotherapies can improve the outcomes aimed at the reduction of recurrence and extension of survival. High-quality research and advances in technologies have contributed to well define the oncological outcomes and have stimulated many clinical studies testing multimodality managements in the advanced disease setting. This review article aims to outline and discuss open issues in current surgical management of advanced gastric cancer.

KW - Advanced gastric cancer

KW - HIPEC

KW - Laparoscopic surgery

KW - Lymphadenectomy

KW - Robotic surgery

UR - http://www.scopus.com/inward/record.url?scp=84953360240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953360240&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2015.10.016

DO - 10.1016/j.ejso.2015.10.016

M3 - Article

VL - 42

SP - 18

EP - 27

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -